# Vericel Corp

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Vericel Corp).

## Overview

Vericel Corp is a U.S.-based biopharmaceutical company focused on advanced therapies for cartilage repair and severe burn care. Its commercial portfolio includes MACI for knee cartilage defects, Epicel for severe burns, and NexoBrid for burn eschar removal in North America through a license and supply arrangement.

## Products & services

• MACI autologous cellularized scaffold for knee cartilage repair
• MACI Arthro arthroscopic delivery system and instruments
• Epicel cultured epidermal autograft for severe burns
• NexoBrid enzymatic burn debridement therapy in North America

- **MACI** (75%) — Autologous cell therapy for repair of symptomatic knee cartilage defects.
- **Epicel** (15%) — Cultured epidermal autograft used for patients with severe burns.
- **NexoBrid** (5%) — Specialty biologic for enzymatic removal of burn eschar in burn care.
- **MACI Arthro and related instruments** (5%) — Arthroscopic delivery tools and accessories used with MACI implants.

- MACI autologous cellularized scaffold for knee cartilage repair
- MACI Arthro arthroscopic delivery system and instruments
- Epicel cultured epidermal autograft for severe burns
- NexoBrid enzymatic burn debridement therapy in North America

## Customers

Vericel sells primarily to hospitals, specialty pharmacies, burn centers, and surgeons that treat patients with cartilage injuries or severe burns. MACI is used by orthopedic surgeons and reimbursed through commercial, government, or hospital channels, while Epicel and NexoBrid are directed to burn centers and hospital-based care teams. The business depends on physician adoption, payer coverage, and institutional purchasing decisions.

- **Orthopedic surgeons and sports medicine centers** (primary) — Buy and implant MACI for symptomatic knee cartilage defects, especially higher-volume arthroscopic surgeons.
- **Hospitals and specialty pharmacies** (primary) — Dispense MACI under payer authorization and manage billing/collection for patient-specific use.
- **Burn centers and hospital burn units** (primary) — Use Epicel and NexoBrid for severe burn treatment and eschar removal.
- **Specialty distributors** (secondary) — Purchase NexoBrid and resell it to hospitals and burn centers.
- **Military and institutional facilities** (secondary) — Buy MACI under contracted arrangements for treatment at military facilities.

- Orthopedic surgeons treating knee cartilage defects with MACI
- Hospitals and specialty pharmacies that dispense MACI to patients
- Burn centers and hospitals treating severe burn patients
- Specialty distributors that resell NexoBrid to care facilities
- Military facilities and institutional buyers for contracted MACI supply

## Geography

Vericel’s operations are concentrated in the United States, where it manufactures, markets, and sells its products. The company states that all operations are located in the U.S. and that 100% of revenue is derived from domestic sales, making its business highly dependent on U.S. reimbursement, regulation, and hospital purchasing patterns.

- **United States** (100%) — Company states all revenue is domestic and all operations are in the U.S.

- All operations are located in the United States
- 100% of revenue is derived from domestic sales
- Manufacturing is centered in Massachusetts
- Commercial activity is focused on U.S. hospitals, burn centers, and surgeons

## Strategy

Vericel’s strategy centers on expanding adoption of its commercial therapies, especially MACI, while broadening surgeon access through MACI Arthro. It also seeks to grow burn care through Epicel and NexoBrid, supported by focused sales teams, payer coverage, and manufacturing scale-up in Massachusetts.

- **Expand MACI surgeon adoption and procedure volume** (short-term) — MACI is the core commercial product and depends on surgeon training and procedural penetration.
- **Build burn care franchise around Epicel and NexoBrid** (medium-term) — Burn care provides a second specialty channel with focused institutional customers.
- **Increase manufacturing capacity and operational resilience** (medium-term) — Cell therapy products require reliable in-house production and validated facilities.

- Expand MACI adoption among higher-volume knee cartilage surgeons
- Drive uptake of MACI Arthro through arthroscopic procedures
- Grow burn care sales through Epicel and NexoBrid
- Scale manufacturing capacity and validate the Burlington facility
- Maintain payer coverage and institutional access for specialty therapies

## Risks

Vericel faces concentration risk in a small number of specialty products, with demand tied to surgeon adoption, burn-center utilization, and payer coverage. Its cell-therapy manufacturing model also creates operational and regulatory risk, while NexoBrid commercialization depends on maintaining licensed rights and achieving market acceptance in the U.S.

- **Quarterly and annual revenue volatility** [high] — Sales depend on procedure timing, seasonal patterns, and burn-care demand.
- **Manufacturing disruption or facility failure** [critical] — Products are biologic therapies requiring controlled in-house production and supply continuity.
- **Payer coverage and reimbursement risk** [high] — MACI shipments require prior authorization and reimbursement can vary by payer.
- **Commercial adoption risk for NexoBrid** [medium] — The product must gain acceptance in a specialized burn-care market to scale meaningfully.
- **Intellectual property and license dependence** [high] — Exclusive commercialization rights for NexoBrid depend on compliance with MediWound agreements.
- **Competition from alternative cartilage and burn treatments** [medium] — Established medical device and biologics companies compete in regenerative medicine and burn care.

- Revenue can fluctuate with procedure timing and burn-case volume
- MACI adoption depends on surgeon training and payer coverage
- Manufacturing disruptions could limit supply of cell therapy products
- NexoBrid depends on licensed rights and commercial execution
- Novel biologic products face regulatory and competitive risk

## Accounting

Vericel recognizes product revenue under ASC 606 when control transfers, but MACI sales through specialty pharmacies require estimates for contractual allowances and collectability. Revenue can be affected by prior authorization timing, payer reimbursement patterns, and patient-specific billing, while stock compensation, lease amortization, and valuation allowances also influence reported results.

- **ASC 606 revenue recognition for MACI** — Patient-specific reimbursement and denial rates affect reported sales
- **Contractual allowances and credit loss estimates** — Can materially change net product revenue and receivables
- **Lease accounting for Massachusetts facilities** — Affects operating expenses and balance sheet obligations
- **Valuation allowance on deferred tax assets** — Can significantly affect tax expense and net income

- MACI revenue depends on estimated contractual allowances and collectability
- Revenue is recognized when control transfers, not when cash is collected
- Specialty pharmacy distribution adds billing and reimbursement judgment
- Lease accounting affects manufacturing and office cost recognition
- Deferred tax assets are subject to valuation allowance assessment

---

*Last updated: 2026-04-29T05:07:44.866521+00:00*